A 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ichorcumab (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 06 Sep 2017 Planned number of patients changed from 56 to 48.
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 16 Jun 2017 Planned End Date changed from 8 Feb 2018 to 23 Jun 2018.